References
- Linden A, Adams JL, Roberts N. Using propensity scores to construct comparable control groups for disease management program evaluation. Dis Manage Health Outcomes 2005;13:107–15
- Ravallion M. The mystery of the vanishing benefits: an introduction to impact evaluation. the world bank economic review 2001;15:115–40
- Gomez R, Romero R, Ghezzi F, et al. The fetal inflammatory response syndrome. Am J Obstet Gynecol 1998;179:194–202
- Wilcken B. Screening for disease in the newborn: the evidence base for blood-spot screening. Pathology-J RCPA 2012;44:73--9
- Haak PT, Busik JV, Kort EJ, et al. Archived unfrozen neonatal blood spots are amenable to quantitative gene expression analysis. Neonatology 2009;95:210–16
- Khoo SK, Dykema K, Vadlapatla NM, et al. Acquiring genome-wide gene expression profiles in Guthrie card blood spots using microarrays. Pathol Int 2011;61:1–6
- Madsen-Bouterse SA, Romero R, Tarca AL, et al. The transcriptome of the fetal inflammatory response syndrome. Am J Reprod Immunol 2009;63:73–92
- Chi JT, Wang Z, Nuyten DSA, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006;3:e47
- Clément K, Viguerie N, Diehn M, et al. In vivo regulation of human skeletal muscle gene expression by thyroid hormone. Genome Res 2002;12:281–91
- Ho NT, Furge KA, Fu W, et al. Gene expression in archived newborn blood spots distinguishes infants who will later develop cerebral palsy from matched controls. Prediatr Res 2012; 73:450–56